Skip to main content
Premium Trial:

Request an Annual Quote

Five RNAi-Related Patent Applications Published by the US Patent Office: Dec 24, 2004


Title: Compositions and Methods for siRNA Inhibition of Angiopoietin1 and 2, and Their Receptor Tie2. Number: 20040248174. Filed: April 19, 2004. Lead Inventor: Samuel Reich, University of Pennsylvania (Acuity Pharmaceuticals).

According to the patent application’s abstract, the invention comprises “RNA interference using small interfering RNAs which are specific for mRNA produced from the Ang1, Ang2, or Tie2 genes inhibits expression of these genes. Diseases which involve Ang1, Ang2, or Tie2 mediated angiogenesis, such as inflammatory and autoimmune diseases, diabetic retinopathy, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs.”

Title: RNAi Arrays and Methods of Using the Same. Number: 20040248164. Filed: March 4, 2004. Lead Inventor: Jen-Tsan Chi, Stanford University School of Medicine.

The patent application, its abstract states, covers assays that “are characterized by having two or more distinct RNAi agents. The arrays find use in methods where cells are contacted with the arrays and the activity of the RNAi agents is determined by evaluating the contacted cells. The subject arrays and methods find use in a variety of applications, such as high throughput loss of function genomic applications,” the abstract adds.

Title: Methods and Compositions Relating to Labeling RNA Molecules That Reduce Gene Expression. Number: 20040248094. Filed: June 12, 2002. Lead Inventor: Lance Ford, Ambion.

“The … invention concerns methods and compositions involving labeled, double-stranded RNA, including siRNA, capable of triggering RNA-mediated interference in a cell,” the patent application’s abstract states. “Compositions of the invention include labeled dsRNA for RNAi, which may be a single strand of RNA that base pairs with itself or two separate RNA strands. In some embodiments, the label is fluorescent. The … invention further concerns methods for preparing such composition and kits for implementing such methods. Other methods of the invention include ways of using labeled dsRNA for RNAi,” the abstract notes.

Title: RNAi-Mediated Gene Modulation. Number: 20040253604. Filed: Sept. 16, 2003. Lead Inventor: Shi-Lung Lin, University of Southern California.

According to the patent application’s abstract, the invention is “an isolated RNA comprising an intron RNA that is released in a cell, thereby modulating the function of a target gene.” The invention also comprises “a chemokine and an isolated RNA of the invention, or a DNA template for the isolated RNA, a composition comprising one or more agents that induce RNA-mediated modulation of the functions of two or more target genes in a cell, and methods of using these compositions for modulating the functions of genes in a cell,” the abstract states.

Title: Phosphorus-Linked Oligomeric Compounds and Their Use in Gene Modulation. Number: 20040254358. Filed: June 12, 2003. Lead Inventor: Muthiah Manoharan, Isis Pharmaceuticals.

The patent application covers “oligonucleotide compositions comprising first and second oligonucleotides … wherein at least a portion of the first oligonucleotide is capable of hybridizing with at least a portion of the second oligonucleotide, at least a portion of the first oligonucleotide is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligonucleotides includes at least one nucleotide having a modified phosphorous-containing internucleoside linkage,” its abstract states. “Oligonucleotide/protein compositions are also provided comprising an oligonucleotide complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex, wherein at least one nucleotide of the oligonucleotide has a modified phosphorous-containing internucleoside linkage.”

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.